Treatment of excessive mediastinal bleeding after cardiopulmonary bypass

被引:17
作者
Hartstein, G [1 ]
Janssens, M [1 ]
机构
[1] UNIV HOSP LIEGE,DEPT ANESTHESIA & INTENS CARE MED,LIEGE,BELGIUM
关键词
D O I
10.1016/S0003-4975(96)00937-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Excessive mediastinal bleeding after cardiopulmonary bypass is one of the most frequently reported complications of cardiac operations. Appropriate treatment requires a rapid and effective diagnostic work-up, based on the knowledge of the pathophysiology induced by cardiopulmonary bypass. Methods. Possible causes, diagnostic methods available, and therapeutic approaches are reviewed in the light of the literature published on excessive bleeding after cardiac operations. Results. When bleeding is massive (>250 to 300 mL/h for the first 2 hours, >150 mL/h thereafter), immediate surgical reexploration is mandatory. When bleeding is less important (50 to 150 mL/h), the decision to reoperate should be based on the presence of hemodynamic compromise or a suspected surgical cause. Otherwise, coagulation testing should allow the correction of hemostatic defects as appropriate with protamine, platelet concentrates, fresh frozen plasma, desmopressin, or antifibrinolytics. Hypothermia and hypotension should be corrected and a trial of positive end-expiratory pressure may be considered if diffuse mediastinal oozing (especially from the bed of the mammary artery) is suspected. Conclusions. A protocol is suggested to guide treatment, taking into account the rapidity of blood loss and the suspected underlying cause.
引用
收藏
页码:1951 / 1954
页数:4
相关论文
共 31 条
[1]   UNORTHODOX USE OF APROTININ TO CONTROL LIFE-THREATENING BLEEDING AFTER CARDIOPULMONARY BYPASS [J].
ANGELINI, GD ;
COOPER, GJ ;
LAMARRA, M ;
BRYAN, AJ .
LANCET, 1990, 335 (8692) :799-800
[2]   Postoperative aprotinin: Effect on blood loss and transfusion requirements in cardiac operations [J].
Cicek, S ;
Demirkilic, U ;
Kuralay, E ;
Ozal, E ;
Tatar, H .
ANNALS OF THORACIC SURGERY, 1996, 61 (05) :1372-1376
[3]  
Czer L S, 1989, J Cardiothorac Anesth, V3, P760, DOI 10.1016/S0888-6296(89)95267-8
[4]   TREATMENT OF SEVERE PLATELET DYSFUNCTION AND HEMORRHAGE AFTER CARDIOPULMONARY BYPASS - REDUCTION IN BLOOD PRODUCT USAGE WITH DESMOPRESSIN [J].
CZER, LSC ;
BATEMAN, TM ;
GRAY, RJ ;
RAYMOND, M ;
STEWART, ME ;
LEE, S ;
GOLDFINGER, D ;
CHAUX, A ;
MATLOFF, JM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (05) :1139-1147
[5]  
Dilthey G, 1993, J Cardiothorac Vasc Anesth, V7, P425, DOI 10.1016/1053-0770(93)90164-G
[6]  
Essell J H, 1993, J Cardiothorac Vasc Anesth, V7, P410, DOI 10.1016/1053-0770(93)90161-D
[7]   APROTININ IN CARDIOPULMONARY BYPASS - EFFECTS ON THE HAGEMAN-FACTOR (FXII) - KALLIKREIN SYSTEM AND BLOOD-LOSS [J].
FUHRER, G ;
GALLIMORE, MJ ;
HELLER, W ;
HOFFMEISTER, HE .
BLOOD COAGULATION & FIBRINOLYSIS, 1992, 3 (01) :99-104
[8]   USE OF ESMOLOL IN HYPERTENSION AFTER CARDIAC-SURGERY [J].
GRAY, RJ ;
BATEMAN, TM ;
CZER, LSC ;
CONKLIN, C ;
MATLOFF, JM .
AMERICAN JOURNAL OF CARDIOLOGY, 1985, 56 (11) :F49-F56
[9]  
HARKER LA, 1980, BLOOD, V56, P824
[10]  
Huyzen R J, 1994, J Cardiothorac Vasc Anesth, V8, P153, DOI 10.1016/1053-0770(94)90054-X